AstraZeneca (AZN): news on Friday 16 October 2026

The 38 stories

Each headline's own score, strongest first. Links go to the publisher.

• +7.5 UBS Maintains AstraZeneca(AZN.US) With Buy Rating, Maintains Target Price $201.17 Moomoo
  UBS maintains Buy rating with high target.
• +7.5 RBC maintains 'outperform' on AstraZeneca, eyes strong lung cancer drug trial data Pluang
  RBC keeps outperform, expects strong trial data.
• +7.0 RBC keeps AstraZeneca at ‘outperform’ ahead of AVANZAR lung cancer trial Proactive financial news
  RBC outperform ahead of lung cancer trial.
• +6.7 AstraZeneca PLC Stock (AZN) Moved Up by 3.55% on Oct 15: What Signal Does It Send? TradingKey
  Shares rose 3.55%.
• +6.7 AstraZeneca Stock Analysis: Gains 3.24%, Testing Key Resistance JournalArta
  Share price gain, testing resistance.
• +6.3 AstraZeneca and insitro Sign USD 1.5 Billion AI Drug Discovery Partnership Analytics Insight
  Large AI partnership worth up to $1.5bn.
• +5.8 AstraZeneca bulks up MASH, cardio work in up to $1.5B AI partnership with insitro BioSpace
  Expands MASH and cardio work via AI partnership.
• +5.8 AI startup Insitro nails deal worth up to $1.4 billion with pharma giant AstraZeneca The Business Journals
  Deal worth up to $1.4bn with AI startup.
• +5.8 AstraZeneca announces insitro collaboration: stock pre-market at EUR 148.70 - ad-hoc-news.de ad-hoc-news.de
  Collaboration announcement with insitro, mildly positive.
• +5.8 AstraZeneca, FDC, Nutricia lead corporate growth as pharma market strengthens in September 2026 BioSpectrum India
  Named as a leading corporate growth performer.
• +5.7 Insitro’s Virtual Human attracts $1.5B MASH deal with Astrazeneca BioWorld News
  Virtual Human platform attracts $1.5bn MASH deal.
• +5.5 AstraZeneca Taps insitro AI for MASH in Deal Worth Up to $1.5 Billion Pharmaceutical Executive
  AI deal for MASH worth up to $1.5bn.
• +5.5 AstraZeneca (LSE:AZN) Enters AI Drug Discovery Partnership In MASH And Cardiomyopathies Yahoo Finance
  AI partnership in MASH and cardiomyopathies.
• +5.5 AstraZeneca And insitro Enter AI Drug Discovery Collaboration Worth Up To Approximately $1.5 Billion Pulse 2.0
  Collaboration worth up to about $1.5bn.
• +5.5 Insitro signs USD 1.5b deal with AstraZeneca to hunt MASH and cardiomyopathy targets with AI AllSci
  Deal targets MASH and cardiomyopathy using AI.
• +5.5 AstraZeneca joins the "AI + pharmaceuticals" boom: partnering with Insitro to develop drugs for fatty liver and cardiac diseases, with a $1.86 billion deal. 富途牛牛
  Joins AI pharma boom with $1.86bn deal.
• +5.3 AstraZeneca Strikes Up to $1.5 Billion AI Drug Discovery Deal With Insitro WSJ
  WSJ reports up to $1.5bn AI deal.
• +5.3 AstraZeneca enters new strategic collaboration with insitro The Pharma Letter
  New strategic collaboration announced.
• +5.3 AstraZeneca Turns to AI to Crack Tough Heart and Liver Diseases in Billion-Dollar Deal Benzinga
  Billion-dollar AI deal for heart and liver disease.
• +5.3 AstraZeneca Bets on AI Drug Discovery in $1.5 Billion Potential Partnership With Insitro Belaaz
  Bets on AI in potential $1.5bn partnership.
• +5.0 AstraZeneca strikes $40 million AI drug discovery deal with insitro Reuters
  Reuters reports AI drug discovery deal.
• +5.0 Astrazeneca (AZN) Rises Higher Than Market: Key Facts Yahoo Finance
  Shares outperformed the market.
• +5.0 AstraZeneca signs $40 million AI drug-discovery agreement with insitro finchannel
  AI drug-discovery agreement signed with insitro.
• +5.0 AstraZeneca enters into strategic drug discovery deal with AI biotech Insitro Sharecast.com
  Strategic drug discovery deal with AI biotech.
• +5.0 AstraZeneca signs AI drug discovery deal for heart and liver diseases MedWatch
  AI drug discovery deal for heart and liver.
• +5.0 AstraZeneca, Insitro strike AI drug discovery deal Fox Business
  AI drug discovery deal reported.
• +5.0 AstraZeneca does AI deal with insitro; inVIOs’ Phase 1 success in solid tumors Endpoints News
  AI deal with insitro reported.
• +5.0 AstraZeneca to Invest Up to $1.5 Billion in AI-Driven Drug Discovery ForkLog
  Invests up to $1.5bn in AI drug discovery.
• +5.0 AstraZeneca, insitro Strike AI Drug Discovery – What Investors Need To Know Stocktwits
  Investor-focused piece on the AI deal.
• +5.0 AstraZeneca signs AI drug discovery deal with insitro worth up to $1.86 billion Crypto Briefing
  AI deal reported, value up to $1.86bn.
• +5.0 AstraZeneca enters drug discovery collab, licensing agreement with insitro TipRanks
  Collaboration and licensing agreement with insitro.
• +4.7 MASH and Cardiomyopathy Targets: Why AstraZeneca Chose insitro’s AI PharmTech.com
  Explains rationale for choosing insitro's AI.
• +4.2 Mubadala takes Clear Channel private, International Paper's bidders, and Astrazeneca's $1.5b deal Axios
  Deal mentioned in a roundup of deals.
• +3.3 How is AI helping scientists design the next generation of biologic medicines? AstraZeneca
  Company content on AI in biologics design.
• +3.3 AstraZeneca Investment Boosts UNICEF Partnership to Improve Adolescent Health in Jamaica UNICEF
  Positive social partnership, minor for the business.
• +3.3 The Zacks Analyst Blog Highlights Mastercard, AstraZeneca and Sandisk Zacks Investment Research
  Included in analyst blog highlights with others.
• +2.5 Pharmalittle: We're reading about former FDA head calling DOGE a 'disaster,' an AstraZeneca AI deal, and more STAT
  AI deal mentioned in a news roundup.
• +1.7 Biotech Stocks Need A Shot In The Arm After Brutal July: Could AstraZeneca-Bristol Myers Megadeal Be The Cure? Stocktwits
  Sector weakness; speculative megadeal mention with Bristol Myers.